Patheon's loss widens on refinancing, acquisition costs
March 8 (Reuters) - Contract drugmaker Patheon Inc reported a wider first-quarter loss on charges related to its acquisition of Banner Pharmacaps.
Loss from continuing operations rose to $51.4 million, or 38 cents per share, from $19.3 million, or 15 cents per share, a year earlier.
Patheon, which provides contract development and manufacturing services to pharmaceutical companies, said revenue rose 39 percent to $213.5 million.
The North Carolina-based company recorded a $29.1 million refinancing charge. It booked acquisition-related costs of $4.4 million and restructuring charges of $4 million.
Patheon bought Banner Pharmacaps last year, which focuses on gelatin-based oral drug delivery technology, for $255 million, to expand its presence in the over-the-counter market and gain a foothold in Mexico.
The company said it also took a $10.1 million charge related to the closure of a manufacturing facility in Alberta.
Patheon shares closed at C$3.64 on the Toronto Stock Exchange on Thursday.